However, the effect of combination therapy and the therapeutic effect for selected patients, such as those with tumors expressing a particular hormone receptor, ERBB2 (HER2) status or those in earlier stages of breast cancer, remain to be determined. Here, ERBB2 is linked to breast carcinoma.